Physician profile
Michael E Dicus
NPI 1447339452
$8,829.73
in general payments reported to CMS, 2019-2025
36 companies · $1,216 in 2025
The $1,216 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,412 · 2020: $947 · 2021: $1,356 · 2022: $1,516 · 2023: $1,292 · 2024: $1,090 · 2025: $1,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,542 · Education: $55.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,542.25 |
| Education | $55.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $1,537.39 | 2019-2025 | Velphoro, Velphoro |
| Amgen INC. | $1,495.26 | 2019-2025 | Tavneos, Parsabiv, Krystexxa |
| Vifor Pharma, INC. | $995.71 | 2019-2025 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $734.16 | 2019-2025 | Lokelma, Farxiga |
| Travere Therapeutics, INC. | $641.43 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $589.63 | 2021-2025 | |
| Glaxosmithkline, LLC. | $373.49 | 2021-2025 | Benlysta |
| Opko Pharmaceuticals, LLC | $360.46 | 2019-2024 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $309.96 | 2019-2024 | Jynarque |
| Aurinia Pharma U.S., INC. | $241.28 | 2021-2025 | Lupkynis |
| Novo Nordisk INC | $211.65 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Calliditas Therapeutics US INC. | $179.17 | 2023-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $163.77 | 2020-2025 | Acthar |
| Horizon Therapeutics Plc | $153.07 | 2020-2022 | |
| Genzyme Corporation | $127.83 | 2019-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $121.86 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $81.97 | 2020-2023 | Ultomiris |
| Mallinckrodt Enterprises LLC | $74.99 | 2019 | |
| Novartis Pharmaceuticals Corporation | $52.63 | 2025 | |
| Ardelyx, INC. | $50.48 | 2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.50 | 2021-2025 | Jardiance |
| Amag Pharmaceuticals, INC. | $37.86 | 2020-2022 | |
| Genentech USA, INC. | $28.79 | 2025 | Gazyva |
| Chiesi USA, INC. | $24.13 | 2024 | Elfabrio |
| Sanofi-Aventis U.S. LLC | $21.97 | 2020 | |
| Biogen, INC. | $20.45 | 2021 | |
| Kyowa Kirin, INC. | $18.50 | 2023 | |
| Janssen Pharmaceuticals, INC | $17.76 | 2019 | |
| Baxter Healthcare | $17.46 | 2019 | |
| Heron Therapeutics, INC. | $17.15 | 2025 | Zynrelef |
| Lilly USA, LLC | $17.12 | 2023 | Jardiance |
| Daiichi Sankyo INC. | $14.98 | 2019 | |
| Hikma Pharmaceuticals USA | $14.02 | 2019 | |
| Avion Pharmaceuticals | $14.01 | 2020 | |
| Ani Pharmaceuticals, INC. | $13.75 | 2025 | Purified Cortrophin Gel |
| Abbott Laboratories | $13.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dicus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.